




# Q1 '22 Earnings Call

12 May 2022



# Disclaimer

## Use of Non-GAAP Financial Measures

This Presentation includes non-GAAP financial measures. Cellebrite believes that these non-GAAP measures are useful to investors for two principal reasons. First, Cellebrite believes these measures may assist investors in comparing performance over various reporting periods on a consistent basis by removing from operating results the impact of items that do not reflect core operating performance. Second, these measures are used by Cellebrite's management to assess its performance. Cellebrite believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. These non-GAAP measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Other companies may calculate these non-GAAP financial measures differently, and therefore such financial measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this Presentation.

## Forward Looking Statements

This Presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "may", "should", "would", "plan", "intend", "expect", "believe", "anticipate", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "outlook", or other similar expressions, words or phrases are intended to identify forward-looking statements. These statements include statements regarding the industry in which Cellebrite operates, future events and other statements that are not historical facts. These statements are made on the basis of current knowledge and current expectations of Cellebrite management and, by their nature, involve numerous assumptions and uncertainties and are not predictions of actual performance. Nothing set forth herein should be regarded as a representation, warranty, or prediction that Cellebrite will achieve or are likely to achieve any particular future result.

Various factors could cause actual future results, performance or events to differ materially from those described herein. This Presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in making an evaluation. The matters discussed in this presentation also involve risks and uncertainties summarized under the heading "Risk Factors" in Cellebrite's 20-F filed with the SEC on March 29, 2022, as amended on April 14, 2022.

Some of the factors that may impact future results and performance may include, without limitation:

- The impact of pending and future litigation and governmental investigations and inquiries;
- Changes in U.S. federal, U.S. state, and non-U.S. laws and regulations, their interpretation, their enforcement, or the regulatory climate applicable to our business, and their impact on our ability to operate our business;
- Errors, failures, defects or bugs in our products, which could expose us to financial and legal harm and adversely affect our operating results and growth prospects; and
- Some of our solutions may be used by customers in a way that is, or that is perceived to be, incompatible with human rights. Any such perception could adversely affect our reputation, revenue and results of operations
- Any non-compliance with the Israeli encryption laws and governmental trade controls, including export and regulations could negatively impact our operating results.

Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




# Business Overview

# Agenda

- 1 Strong Quarter Results
- 2 Healthy Market Environment
- 3 Growth Potential within Existing Customers

# 1 Strong Q1 2022 results



# Growth pillars



Increase Wallet Share in Existing Accounts



Continued Product Innovation





# 2 Market environment



Quantity, Variety and Complexity of Digital Evidence




Inefficiency and Siloed, Manual Process



Available Funding

# Digital evidence challenges

## Internet Crime in the US



Source: the FBI Internet Crime Report 2021

■ Complaints ■ Losses

## Backlog in the UK



Source: Channel4 News

# 3 Massive growth potential within existing customers



## Federal

100+ North American  
Federal Accounts

15 of 15 U.S Cabinet  
Executive Departments



27 of 27 member E.U.  
National Police



## State, Local & Government

2,800+ North American  
State and Local Accounts

50 of 50 U.S. States

Police Departments at  
20 of Largest 20 U.S. Cities

Police Departments at  
13 of Largest 20 Cities in Europe



## Private Sector

68 of Fortune 100

8 of Top 10 U.S.  
Commercial Banks

9 of Top 10  
Accounting Firms

7 of Top 10  
Pharma Companies

6 of Top 10  
Telecom companies

8 of Top 10 U.S.  
Software Companies

Based on FY2021 data.

Sources: Fortune, Wikipedia, big4accountingfirms.org. Largest cities refers to population.



# Q1 '22 Customer success

1

## Expansion outside the Forensic Lab



### National Police Force

- ★ \$2M, multi year
- ★ Over 100 police stations
- ★ One of the largest Premium Enterprise deployments to date

2

## Up the Value Chain



### National Police Force

- ★ ~\$3M, multi year
- ★ Collect & Review, Investigative Analytics
- ★ Faster, more accurate results: 6 weeks work down to 2 hours

3

## Resource Augmentation



### Municipal Police Force

- ★ ~\$0.7M
- ★ Outsourcing Advanced Access
- ★ Backlog reduction effort



# Executing on 2022 plan



Go to market investment facilitates higher level discussion



Advanced capabilities to the broader customer base through a cloud solution



Partnership to seamlessly integrated cryptocurrency into investigation suite




Cellebrite  
**PREMIUM** x





# Financial Overview

# ARR growth driven by expansion




# Revenue growth driven by subscription



# Investing in our growth

Operating expenses  
(Non-GAAP, \$M)  
and % of sales



785

Headcount Mar-21



920

Headcount Mar-22




1,000+


Headcount Target Dec-22

# Operating leverage and solid cash position

Adj. EBITDA (\$M) and margin



Cash position



# Financial forecast

	2022E
ARR	\$250-265M
ARR Growth	34-42%
Revenue	\$285-300M
Revenue Growth	16-22%
Gross Margin	80-82%
Adjusted EBITDA	\$39-44M
Adjusted EBITDA Margin	13-15%



# Q&A

# Appendix

# Financial summary Q1 22

<i>(\$K)</i>	<b>Mar 21</b>	<b>Mar 22</b>
<b>ARR</b>	<b>150,480</b>	<b>200,543</b>
<i>YOY Growth - %</i>	<i>53%</i>	<i>33%</i>
Subscriptions	40,521	48,185
Perpetual License & Others	7,743	5,672
Professional Services	5,019	8,228
<b>Total Revenue</b>	<b>53,283</b>	<b>62,385</b>
<i>YOY Growth - %</i>	<i>38%</i>	<i>17%</i>
<b>Gross Profit</b>	<b>45,084</b>	<b>55,572</b>
<i>Gross Profit - %</i>	<i>84.6%</i>	<i>82.4%</i>
<b>Adjusted EBITDA</b>	<b>11,288</b>	<b>4,081</b>
<i>Non-GAAP EBITDA - %</i>	<i>21.2%</i>	<i>6.5%</i>



# Adjusted EBITDA reconciliation Q1 22

(\$K)	Mar 21	Mar 22
<b>Net Income</b>	<b>3,590</b>	<b>55,438</b>
Financial income, net	(366)	(56,400)
Tax expenses	1,163	(984)
Share based compensation	1,699	2,858
Amortization of intangible assets	388	664
Acquisition related costs	3,721	1,058
<b>Non-GAAP EBIT</b>	<b>10,195</b>	<b>2,634</b>
<i>Non-GAAP EBIT - %</i>	<i>19.1%</i>	<i>4.2%</i>
Depreciation & Amortization	1,093	1,448
<b>Adjusted EBITDA</b>	<b>11,288</b>	<b>4,082</b>
<i>Adj EBITDA - %</i>	<i>21.2%</i>	<i>6.5%</i>



# Definitions

1. **Annual Recurring Revenue:** Annual recurring revenue (“ARR”) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12.
2. **Subscription Revenue:** Is defined as revenue from recurring, term-based license contracts and ongoing services related to core offerings. Subscription revenue is recognized ratably over the subscription term with a portion of revenue, related to the term-based license, recognized upfront.
3. **Net Retention:** Dollar-based net retention rate is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.
4. **Gross Retention:** Gross revenue retention is calculated by dividing customer revenue excluding upsells by base revenue. We define base revenue as revenue we recognize from all customers in the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define customer revenue excluding upsells as the revenue we recognize during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, excluding upsells / cross-sells. The measure captures the weighted average dollar loss versus 100% from the customer base.

